Shares of Indivior PLC (LON:INDV – Get Free Report) dropped 17% during trading on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 720.60 ($9.10). Approximately 2,904,792 shares changed hands during trading, an increase of 294% from the average daily volume of 737,710 shares. The stock had previously closed at GBX 868 ($10.97).
Analyst Upgrades and Downgrades
Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,800 ($22.74) price objective on shares of Indivior in a report on Tuesday, December 17th.
View Our Latest Report on INDV
Indivior Stock Performance
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Roth IRA Calculator: Calculate Your Potential Returns
- DuPont’s Electronics Spinoff: The Start of Something Big
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.